MMJ BioPharma Cultivation and Native American Tribe Moving Forward With Marijuana DEA Application

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

ST. PETERSBURG, FL / ACCESSWIRE / July 14, 2019 / MMJ BioPharma Cultivation has applied for a DEA Schedule-I Bulk Manufacturer license to cultivate cannabis plants to support MMJ International Holdings investigational new drug (IND) filings with the FDA for Multiple Sclerosis and Huntington’s disease. It will also plan to meet the growing demand from hospitals, researchers, and scientist for their FDA/DEA approved clinical trials. MMJ BioPharma Cultivation will facilitate a process of scientific drug development and discovery governed by FDA protocol development processes and DEA regulatory manufacturing guidelines.

To further meet the statutory requirements of the “public benefit” MMJ BioPharma Cultivation has entered into an agreement with a US Native Indian Tribe to perform its development activities. MMJ BioPharma Cultivation is planning a phased development program on Native American Tribal Trust lands of approximately 1 million square feet with a state of the art extraction analytics lab to meet DEA approved researchers needs. MMJ BioPharma Cultivation will be employing tribal members in its development and cultivation program.

Dr. Elio Mariani, a senior executive of the company and big pharma veteran stated “we are looking forward to our collaboration with the tribe in unlocking the potential of cannabinoid medicines to address serious medical conditions. Our efforts will be guided by the FDA and DEA as we strive to produce the highest pharma grade plants and extracts for clinical research.”

Duane Boise, CEO of the company further stated, “At MMJ BioPharma Cultivation, we are nurturing the quality and effectiveness of medical marijuana through the careful cultivation of cannabis plants in the United States. Our goal is to provide the purest, highest quality pharma grade medicinal marijuana for patients dealing with pain and chronic illness.”

For further information please see: http://mmjbiopharmacultivation.com/.

CONTACT:

Michael Sharpe
800-586-7863
media@mmjih.com

SOURCE: MMJ BioPharma Cultivation

View source version on accesswire.com:
https://www.accesswire.com/551913/MMJ-BioPharma-Cultivation-and-Native-American-Tribe-Moving-Forward-With-Marijuana-DEA-Application

user

Recent Posts

PreveCeutical Announces Update to Non-Brokered Private Placement

Vancouver, British Columbia--(Newsfile Corp. - April 2, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB:…

2 hours ago

Lam Research Corporation Announces March Quarter Financial Conference Call

FREMONT, Calif., April 2, 2025 /PRNewswire/ -- Lam Research Corp. (NASDAQ: LRCX) today announced that…

4 hours ago

Former Pfizer R&D Chief Mikael Dolsten Joins Formation Bio to Chair Drug Picking Committee and Co-Chair its Investment Advisory Committee

NEW YORK, April 2, 2025 /PRNewswire/ -- Formation Bio, an AI-driven pharmaceutical company revolutionizing drug development,…

4 hours ago

Siemens acquires Dotmatics to extend AI-powered software portfolio to Life Sciences

Acquisition of Dotmatics, a leader in Life Sciences R&D software for $5.1 billionExpands Siemens' market-leading…

4 hours ago

PerZeption Appoints CTO to Enhance Visual Function Assessments

BOSTON, April 2, 2025 /PRNewswire/ -- PerZeption Inc., a U.S. vision diagnostics startup dedicated to…

4 hours ago

Dotmatics Signs Definitive Agreement to be Acquired by Siemens Advancing a New Era of AI-Driven Innovation in Life Sciences

Siemens AG will acquire Dotmatics from global software investor Insight Partners for $5.1 billionAcquisition accelerates…

4 hours ago